stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Revenue
Denali Therapeutics Inc.'s revenue for fiscal 2023 was $330.5M, up 204.7% from $108.5M in fiscal 2022. Over the twelve months to 30 September 2026 it was $22.6M. Over the past ten years it has ranged from $26.7M (fiscal 2019) to $335.7M (fiscal 2020); the current reading is higher than 83% of that period. Denali Therapeutics Inc. ranks 177th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2023 | $330.5M | 204.74% |
| FY2022 | $108.5M | 122.90% |
| FY2021 | $48.7M | (85.50%) |
| FY2020 | $335.7M | 1,158.19% |
| FY2019 | $26.7M | (79.34%) |
| FY2018 | $129.2M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $17.8M | 393.29% |
| Jun 2026 | $3.6M | — |
| Dec 2023 | $0.00 | — |
| Sep 2023 | $1.3M | (99.57%) |
| 22 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| TARS Tarsus Pharmaceuticals, Inc. compare | $682.2M |
| IDYA IDEAYA Biosciences, Inc. compare | $36.5M |
| VRDN Viridian Therapeutics, Inc. compare | $26.3M |
| DNLI Denali Therapeutics Inc. | $22.6M |
| VKTX Viking Therapeutics, Inc. compare | — |
| TLX Telix Pharmaceuticals Limited compare | — |
| CELC Celcuity, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
| ELVN Enliven Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on DNLI
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement